Current BTA guidelines and statements

The following are in chronological order with the most recent first:

1st December 2019

Radioiodine has been used very effectively to treat thyroid overactivity since the 1940’s, but a recent study has cast doubt on its safety, causing considerable concern. A joint position statement from the British Thyroid Association and Society for Endocrinology highlights important limitations of this study which may confound its conclusions and calls for caution in interpretation of its results

October 2017

The BTA has responded to the ongoing consultation process by NHS England on prescription of Liothyronine (T3) in primary care. The full response can be found here

2016

Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)?

2015

Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee

Click here

2014

The British Thyroid Association Guidelines for the Management of Thyroid Cancer

Click here

2007

Armour Thyroid (USP) and combined thyroxine/tri-iodothyronine as Thyroid Hormone Replacement

Click here

2006

The UK Guidelines for the use of Thyroid Function Tests

Click here

Guidelines from other bodies

We are responsible for the development and production of guidelines in various thyroidology subject areas but in principle will endorse guidelines prepared by other societies.

Please click here to download our Guidelines Endorsement Statement